Insights on the Interaction between Transthyretin and Aβ in Solution. A Saturation Transfer Difference (STD) NMR Analysis of the Role of Iododiflunisal

• Published in: Journal of medicinal chemistry Vol. 60; no. 13; pp. 5749 - 5758
• Main Authors: Gimeno, Ana, Santos, Luis M, Alemi, Mobina, Rivas, Josep, Blasi, Daniel, Cotrina, Ellen Y, Llop, Jordi, Valencia, Gregorio, Cardoso, Isabel, Quintana, Jordi, Arsequell, Gemma, Jiménez-Barbero, Jesús
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 13.07.2017
• Subjects: Alzheimer Disease - drug therapy; Alzheimer Disease - metabolism; Amyloid beta-Peptides - chemistry; Amyloid beta-Peptides - metabolism; Crystallography, X-Ray; Diflunisal - analogs & derivatives; Diflunisal - chemistry; Diflunisal - pharmacology; Humans; Magnetic Resonance Spectroscopy; Molecular Docking Simulation; Prealbumin - chemistry; Prealbumin - metabolism; Protein Interaction Maps - drug effects
• ISSN: 0022-2623; 1520-4804
• DOI: 10.1021/acs.jmedchem.7b00428

Several strategies against Alzheimer disease (AD) are directed to target Aβ-peptides. The ability of transthyretin (TTR) to bind Aβ-peptides and the positive effect exerted by some TTR stabilizers for modulating the TTR–Aβ interaction have been previously studied. Herein, key structural features of the interaction between TTR and the Aβ(12–28) peptide (3), the essential recognition element of Aβ, have been unravelled by STD-NMR spectroscopy methods in solution. Molecular aspects related to the role of the TTR stabilizer iododiflunisal (IDIF, 5) on the TTR–Aβ complex have been also examined. The NMR results, assisted by molecular modeling protocols, have provided a structural model for the TTR–Aβ interaction, as well as for the ternary complex formed in the presence of IDIF. This basic structural information could be relevant for providing light on the mechanisms involved in the ameliorating effects of AD symptoms observed in AD/TTR± animal models after IDIF treatment and eventually for designing new molecules toward AD therapeutic drugs.